Lapatinib Terminated Phase 2 Trials for Advanced Breast Cancer / HER2/Neu-positive Breast Cancer / Cancer, Breast / Metastatic Breast Cancer (MBC) Treatment

TerminatedTreatment2 IdentifierTitleDrugs
NCT00496366Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
NCT00759642Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
NCT00225758Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy
NCT00903656Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy
NCT01161368A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients
NCT01477060Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer
NCT01534455Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)
NCT00657137APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)
NCT00756470Phase II Neoadjuvant in Inflammatory Breast Cancer
NCT00754702Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
NCT00499681PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE